Shire plc (SHPG) to Update on R&D Pipeline at Investor Day; Enters Collaboration with CFFT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
PTC Therapeutics (PTCT) Gains on Takeover Speculation
December 9, 2014 12:25 PM ESTPTC Therapeutics (NASDAQ: PTCT) gains on takeover speculation after DealReporter said Shire plc (NASDAQ: SHPG)
and Sanofi (NYSE: SNY) are potential suitors for the company.
BofA/Merrill Lynch Downgrades Shire (SHPG) to Neutral
December 9, 2014 6:26 AM ESTBofA/Merrill Lynch downgraded Shire (NASDAQ: SHPG) from Buy to Neutral with a price target of $226.00 (from $220.00) on a more balanced risk/reward.
Analyst Graham Parry cited: "(1) we believe Shires growth potential is now widely recognised (most sellside Buys in sector... More
Sangamo Biosciences (SGMO) Issues Encouraging Update on IVPRP as LSD, Hemophilia Treatment
December 8, 2014 7:11 AM ESTSangamo Biosciences (Nasdaq: SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014.
The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and... More
